Table 1.
Baseline demographic and clinical characteristics of patients assessed before HSCT because of high-risk for development SOS.
| N | DS | Age/Gender | Reason for baseline FS | N of factors | Donor | Planned protocol | Actual protocol | LSM kPa | Specific decisions per FS | Type of change | SOS after HSCT/severity |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | AML | 22/F | -2nd HSCT/ Multiple lines of Tx/Active disease/TBI | 4 | Haplo father | TBF | FLUTBI | 10.1 | No DAC | Composition change | No |
| 2 | sAML | 40/F |
-2nd HSCT -Multiple lines of Tx -DAC |
3 | Haplo brother | TBF-RIC | TBF-RIC | 7 | No specific decision | No | Yes/Moderate |
| 3 | AML | 23/M | Elevated liver enzymes | 1 | Sibling 10/10 | FLUBU4 | BUCY | 4.9 | Despite liver enzymes elevation - MAC BUCY | Intensification | No |
| 4 | sAML | 42/F |
-Alcohol abuse -Fatty liver |
2 | MUD 10/10 | FLUBU4 | FLU Treo 14 | 7.4 | Treo instead of BU | Composition change | Yes/Mild |
| 5 | AML | 60/F |
-Age -2nd HSCT -Multiple lines of Tx - Previous post CTX severe liver toxicity |
4 | Sibling 10/10 | FLUBU2 | FLU Treo 12 | 3.3 | RTC instead RIC | Intensification | No |
| 6 | MF | 37/M |
-MF -Severe splenomegaly -Susp PHTN |
3 | MUD 10/10 | TBF | TBF MUC | 10.2 | No specific decision | No | No |
| 7 | MF | 51/M |
-MF - Severe PHT d/t Portal vein thrombosis - Previous post CTX severe liver toxicity |
3 | Sibling 10/10 | TBF | FLU Treo 12 | 22.5 | Liver biopsy –N, No DAC, No BU, No MTX | Composition change | Very Severe/death |
| 8 | sAML | 65/F |
- Age - Fatty liver with NASH + liver cirrhosis - Past CTX for Ca of Breast |
4 | Haplo son | TBF | Baltimore RIC protocol mini dose FCYTBI 200 RAD | 18 | RIC/No DAC/Prophylactic Defibrotide | Composition change+ Deintensification | No |
| 9 | MF | 46/M |
-MF -Severe splenomegaly -Susp PHTN |
3 | Haplo son | TBF MAC | TBF RIC | 11.6 | RIC | Deintensification | No |
| 10 | MF | 65/M |
-MF -Severe splenomegaly -Susp PHTN -Age -Fatty liver disease |
5 | Sibling 10/10 | TBF | TBF RIC | 13.8 | RIC | Deintensification | No |
| 11 | sAML | 43/F |
-Active disease -Primary hemochromatosis -Periodic Elevated liver enzymes |
3 | Sibling 10/10 | FLUBU4 or FLU Treo12 | FLU Treo12 | 5.1 | RTC | No specific decision | No |
CTX chemotherapy, MF myelofibrosis, VV Vidaza + Venetoclax, DLBCL Diffuse large B-cell lymphoma, TBI total Body irradiation, FLU fludarabin, RIC reduced intensity conditioning, MUD matched unrelated donor, TBF Thiothepa + Busulfan + Fludarabin, BUCY Busulfan + Cytoxan, MUC myelo-ablative conditioning, FC Fludarabin + Cytoxan.